Literature DB >> 22456486

Endothelial chimerism after ABO-incompatible kidney transplantation.

Tatsu Tanabe1, Hideki Ishida, Shigeru Horita, Kazuho Honda, Yutaka Yamaguchi, Katsuya Nonomura, Kazunari Tanabe.   

Abstract

BACKGROUND: Endothelial chimerism in transplanted organs can be defined as the presence of recipient-derived endothelial cells in the donor organ. The mechanism of endothelial chimerism is not well understood and remains controversial. The purpose of this study was twofold. First, we investigated the presence of chimerism in renal allografts of ABO-incompatible kidney transplantation recipients. Second, we analyzed the association between chimerism and the clinical course and histopathological changes.
METHODS: We investigated the presence of chimerism in renal allografts of ABO-incompatible kidney transplantation recipients by immunohistochemical detection of blood type A and B antigens and assessed the association between chimerism, the clinical course, and histopathological changes. Among a total of 56 patients (29 blood group A incompatible and 27 blood group B incompatible), 49 cases (28 blood group A incompatible and 21 blood group B incompatible) were enrolled in this study. Blood group antigens were stained using immunohistochemistry.
RESULTS: Twelve of the 49 patients (12/49, 24.5%) exhibited endothelium chimerism in a biopsy sample. Among the 12 patients with endothelium chimerism, 7 patients (7/12, 59%) had acute and chronic active antibody-mediated rejection and 2 patients (2/12, 17%) had severe calcineurin inhibitor toxicity. The graft survival rate in the chimerism group was significantly lower than that in the no-chimerism group ([chimerism vs. no-chimerism] 3 years, 83.3% vs. 97.1%; 5 years, 74.1% vs. 97.1%; 8 years, 46.3% vs. 97.1%; P<0.0001).
CONCLUSIONS: Endothelial chimerism seems to be a hallmark of vigorous immune or nonimmune responses, such as antibody-mediated rejection or calcineurin inhibitor toxicity, and not of the induction of tolerance.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22456486     DOI: 10.1097/TP.0b013e31824612b5

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  11 in total

1.  Blood Group A antigen expression on cardiac endothelium is highly individualized: possible implications for transplantation.

Authors:  Eric A Gehrie; Justin M Cates; Hui Nian; Sandy J Olson; Pampee P Young
Journal:  Cardiovasc Pathol       Date:  2013-01-04       Impact factor: 2.185

2.  Computed tomography findings in ABO-incompatible living donor liver transplantation recipients with biliary strictures.

Authors:  Sang Hyun Choi; Kyoung Won Kim; So Yeon Kim; Jin Sil Kim; Jae Hyun Kwon; Gi-Won Song; Sung-Gyu Lee
Journal:  Eur Radiol       Date:  2018-01-02       Impact factor: 5.315

3.  ABO-incompatible living donor kidney transplantation without post-transplant therapeutic plasma exchange.

Authors:  Julie M Yabu; Magali J Fontaine
Journal:  J Clin Apher       Date:  2015-03-05       Impact factor: 2.821

4.  Pulmonary endothelial chimerism after hematopoietic stem cell transplantation.

Authors:  Kyoko Hijiya; Toyofumi Fengshi Chen-Yoshikawa; Aya Miyagawa-Hayashino; Tadakazu Kondo; Akihiro Aoyama; Hironori Haga; Akifumi Takaori-Kondo; Hiroshi Date
Journal:  Surg Today       Date:  2017-07-08       Impact factor: 2.549

Review 5.  Current Perspectives in ABO-Incompatible Kidney Transplant.

Authors:  Federica Maritati; Claudia Bini; Vania Cuna; Francesco Tondolo; Sarah Lerario; Valeria Grandinetti; Marco Busutti; Valeria Corradetti; Gaetano La Manna; Giorgia Comai
Journal:  J Inflamm Res       Date:  2022-05-25

Review 6.  Strategies to overcome the ABO barrier in kidney transplantation.

Authors:  Georg A Böhmig; Andreas M Farkas; Farsad Eskandary; Thomas Wekerle
Journal:  Nat Rev Nephrol       Date:  2015-09-01       Impact factor: 28.314

7.  A donor thrombomodulin gene variation predicts graft-versus-host disease development and mortality after bone marrow transplantation.

Authors:  Haruka Nomoto; Akiyoshi Takami; J Luis Espinoza; Keitaro Matsuo; Shohei Mizuno; Makoto Onizuka; Koichi Kashiwase; Yasuo Morishima; Takahiro Fukuda; Yoshihisa Kodera; Noriko Doki; Koichi Miyamura; Takehiko Mori; Shinji Nakao; Shigeki Ohtake; Eriko Morishita
Journal:  Int J Hematol       Date:  2015-08-06       Impact factor: 2.490

Review 8.  Endothelial Cells in Antibody-Mediated Rejection of Kidney Transplantation: Pathogenesis Mechanisms and Therapeutic Implications.

Authors:  Shuo Wang; Chao Zhang; Jina Wang; Cheng Yang; Ming Xu; Ruiming Rong; Tongyu Zhu; Dong Zhu
Journal:  J Immunol Res       Date:  2017-02-01       Impact factor: 4.818

9.  A novel MSC-based immune induction strategy for ABO-incompatible liver transplantation: a phase I/II randomized, open-label, controlled trial.

Authors:  Yingcai Zhang; Jiebin Zhang; Huimin Yi; Jun Zheng; Jianye Cai; Wenjie Chen; Tongyu Lu; Liang Chen; Cong Du; Jianrong Liu; Jia Yao; Hui Zhao; Guoying Wang; Binsheng Fu; Tong Zhang; Jian Zhang; Genshu Wang; Hua Li; Andy Peng Xiang; Guihua Chen; Shuhong Yi; Qi Zhang; Yang Yang
Journal:  Stem Cell Res Ther       Date:  2021-04-16       Impact factor: 6.832

10.  Effect of simultaneous presence of anti-blood group A/B and -HLA antibodies on clinical outcomes in kidney transplantation across positive crossmatch: a nationwide cohort study.

Authors:  Hyunwook Kwon; Jee Yeon Kim; Dong Hyun Kim; Youngmin Ko; Ji Yoon Choi; Sung Shin; Joo Hee Jung; Young Hoon Kim; Duck Jong Han
Journal:  Sci Rep       Date:  2019-12-03       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.